Related Experiment Videos
Comparison of aspirin with a thromboxane antagonist for patients with prolonged chest pain and ST segment depression
R M Norris1, H D White, H H Hart
1Coronary Care Unit, Green Lane Hospital, Auckland.
Insights
A study found that thromboxane antagonist GR3219 did not reduce chest pain frequency more than aspirin in patients with prolonged chest pain and ST segment depression. Both treatments showed similar outcomes in preventing recurrent chest pain attacks.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Prolonged chest pain with ST segment depression indicates potential acute coronary syndrome.
- Aspirin is a standard antiplatelet therapy, but its efficacy in reducing recurrent chest pain in this specific context requires further investigation.
Purpose of the Study:
- To evaluate if a thromboxane antagonist (GR3219) is more effective than aspirin in reducing the frequency of chest pain attacks.
- To compare the anti-ischemic effects of GR3219 and aspirin in patients presenting with chest pain and ST segment depression.
Main Methods:
- A randomized trial leg comparing GR3219 (80 mg twice daily) with aspirin (300 mg daily) in patients under 76 admitted to a coronary care unit.
- Patients experienced continuous chest pain within 6 hours and showed at least 1 mm of ST segment depression on ECG.
- Pain frequency was monitored via patient diaries over 31 days.
Main Results:
- Seventy percent of all patients experienced recurrent chest pain within the 31-day study period.
- No significant difference was observed in the pattern or frequency of recurrent chest pain between the GR3219 and aspirin groups.
Conclusions:
- The study did not support the hypothesis that thromboxane A blockade with GR3219 is superior to aspirin for reducing chest pain frequency.
- GR3219 did not demonstrate enhanced efficacy over aspirin in this patient population with prolonged chest pain and ST segment depression.
Aim:
To compare a thromboxane antagonist (GR3219) with aspirin in patients with prolonged chest pain and ST segment depression to see if the frequency of attacks of chest pain was reduced.
Methods:
The trial was part of a study comparing GR3219 with aspirin, and streptokinase with placebo and comprised the GR3219/aspirin leg. Thirty one patients were randomly assigned to GR3219 80 mg twice daily and 28 to aspirin 300 mg daily. The patients were under the age of 76 and admitted to a coronary care unit within 6 hours of continuous chest pain. The ECG showed at least 1 mm of flat or down-going ST segment. The patients kept diaries of their pain over the subsequent 31 days.
Results:
Seventy percent of patients developed further chest pain. There was no difference between the pattern of recurrent chest pain according to which drug was used.
Conclusions:
The hypothesis that specific thromboxane A blockade with GR3219 would be more efficacious than aspirin was not supported by these results.